- Home
- EDTK vs PMCB Comparison
EDTK vs PMCB Comparison
Compare EDTK & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDTK
- PMCB
- Stock Information
- Founded
- EDTK 2013
- PMCB 1996
- Country
- EDTK China
- PMCB United States
- Employees
- EDTK N/A
- PMCB N/A
- Industry
- EDTK Other Consumer Services
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EDTK Real Estate
- PMCB Health Care
- Exchange
- EDTK Nasdaq
- PMCB Nasdaq
- Market Cap
- EDTK 16.5M
- PMCB 13.9M
- IPO Year
- EDTK 2020
- PMCB N/A
- Fundamental
- Price
- EDTK $1.09
- PMCB $1.67
- Analyst Decision
- EDTK
- PMCB
- Analyst Count
- EDTK 0
- PMCB 0
- Target Price
- EDTK N/A
- PMCB N/A
- AVG Volume (30 Days)
- EDTK 10.9K
- PMCB 14.9K
- Earning Date
- EDTK 12-31-2024
- PMCB 12-13-2024
- Dividend Yield
- EDTK N/A
- PMCB N/A
- EPS Growth
- EDTK N/A
- PMCB N/A
- EPS
- EDTK N/A
- PMCB 0.54
- Revenue
- EDTK $1,999,056.00
- PMCB N/A
- Revenue This Year
- EDTK N/A
- PMCB N/A
- Revenue Next Year
- EDTK N/A
- PMCB N/A
- P/E Ratio
- EDTK N/A
- PMCB $3.27
- Revenue Growth
- EDTK N/A
- PMCB N/A
- 52 Week Low
- EDTK $0.77
- PMCB $1.39
- 52 Week High
- EDTK $1.34
- PMCB $2.58
- Technical
- Relative Strength Index (RSI)
- EDTK 59.28
- PMCB 44.71
- Support Level
- EDTK $0.97
- PMCB $1.62
- Resistance Level
- EDTK $1.04
- PMCB $1.80
- Average True Range (ATR)
- EDTK 0.06
- PMCB 0.17
- MACD
- EDTK 0.01
- PMCB -0.00
- Stochastic Oscillator
- EDTK 86.24
- PMCB 28.95
About EDTK Skillful Craftsman Education Technology Limited
Skillful Craftsman Education Technology Ltd provides online education and technology services in China. The services comprises of two aspects - Online vocational training and Virtual simulation experimental training. It covers a wide range of subjects, including mechanics, electronics, auto repair and construction. Majority of its revenues are generated from the People's Republic of China.
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.